The past few years have been challenging for the biotech.

Growing revenues from Casgevy will help CRISPR Therapeutics fund the development of its pipeline therapies. The gene-editing biotech isn't profitable yet.

Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It's a great idea to select tomorrow's potential winners and hold on as their stories unfold.

CRISPR Therapeutics AG NASDAQ: CRSP stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.

CRISPR Therapeutics is rated 'Buy' for its blockbuster CASGEVY launch, robust cash position, and high upside despite significant risks. CASGEVY's gene-editing therapy targets severe SCD and TDT, with modeled 2030 peak sales of $5.8B and orphan exclusivity until 2031. DCF-based fair value is $91.95, implying 73% upside with 57% revenue CAGR 2026-2035, but more conservative scenarios suggest CRSP might be fairly valued.

CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

The company could finally be ready to deliver on years of promise.

CRISPR Therapeutics AG is commercially validated with CASGEVY but remains financially unproven and operates at a loss despite strong cash reserves. Incremental buying is attractive now for patient CRSP investors, with major upside expected as revenue scales and normalized EPS turns positive, likely post-2027. The 60/40 global profit split with Vertex offers operating leverage, positioning CRSP for free cash flow as adoption and execution improve.

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Buying biotech stocks is a great way to add growth to your portfolio. This particular player won approval for its first product a couple of years ago, proving the strength of its game-changing technology.